UPTAKE AND DIFFUSION OF PHARMACEUTICAL INNOVATIONS IN HEALTH SYSTEMS - Innovation in the Biopharmaceutical Industry - page 106

Schwermann, T, W Greiner and JM Von der Schulenburg (2003). Using disease manage-
ment and market reforms to address the adverse economic effects of drug budgets
and price and reimbursement regulations in Germany. Value in Health , 6 (Suppl 1),
S20-S30.
Sclar, DA et al . (1994). Antidepressant pharmacotherapy: economic outcomes in a health
maintenance organization. Clinical Therapeutics , 16(4), 715-730.
Seddon, ME et al . (2001). Quality of ambulatory care after myocardial infarction among
Medicare patients by type of insurance and region. American Journal of Medicine ,
111(1), 24-32.
Sheldon, TA et al . (2004). What's the evidence that NICE guidance has been implemented?
Results from a national evaluation using time series analysis, audit of patients' notes,
and interviews. British Medical Journal , 329(7473).
Sheridan, D (2006). Development and innovation in cardiovascular medicine. Imperial
College London Discussion Paper.
Soumerai, SB (1990). Withdrawing payment for nonscientific drug therapy: intended and
unexpected effects of a large-scale natural experiment. Journal of American Medical
Association , 263(6), 831-839.
Soumerai, SB et al . (1987). Payment restrictions for prescription drugs under Medicaid:
effects on therapy, cost, and equity. New England Journal of Medicine , 317(9), 550-
556.
Soumerai, SB et al . (1991). Effects of medicaid drug-payment limits on admission to hos-
pitals and nursing homes. New England Journal of Medicine , 325(15), 1072-1077.
Soumerai, SB et al . (1994). Effects of a limit on Medicaid drugreimbursement benefits
on the use of psychotropic agents and acute mental health services by patients with
schizophrenia. New England Journal of Medicine , 331(10), 650-655.
Stewart-Brown, S et al . (1995). The effects of fundholding in general practice on prescribing
habits three years after introduction of the scheme. BritishMedical Journal , 311(7019),
1543-1547.
Stuart, B (1998). Ability to pay and the decision to medicate. Medical Care , 36(2), 202-211.
Stuart, B et al . (1991). Patterns of outpatient prescription drug use among Pennsylvania
elderly. Health Care Financing Review , 12(3), 61-72.
Stuart, B and NE Coulson (1993). Dynamic aspects of prescription drug use in an elderly
population. Health Services Research , 28(2), 237-264.
Stuart, B and C Zacker (1999). Who bears the burden of Medicaid drug copayment policies?
Health Affairs , 18(2), 201-212.
Szymanski, S and T Valletti (2005). Parallel trade, price discrimination, investment and
price caps. Economic Policy , (44).
Tamblyn, R et al . (2001). Adverse events associated with prescription drug cost-sharing
among poor and elderly persons. Journal of American Medical Association , 285(4),
421-429.
Tidd, J (2000). From Knowledge Management to Strategic Competence: measuring Tech-
nological, Market and Organizational Innovation . London: Imperial College Press.